India's Pharmaceutical Crisis: Reforming Drug Regulation for Global Trust

Why in News?

In late 2022 and early 2023, the global healthcare community was shaken by a series of tragic events linked to Indian-made pharmaceuticals. Dozens of children in The Gambia and Uzbekistan died after consuming contaminated cough syrups, which were found to contain industrial solvents like diethylene glycol (DEG) and ethylene glycol (EG). These incidents cast a harsh spotlight on India’s pharmaceutical industry, long celebrated as the ‘Pharmacy of the World’. The World Health Organization (WHO) issued multiple global alerts, triggering intense international scrutiny and prompting a wave of urgent, comprehensive reforms within India’s drug regulatory ecosystem. This crisis has become a pivotal moment, forcing a nationwide reckoning with the deep-seated structural flaws in its drug safety and quality control mechanisms.

Fun Fact: India is the world’s largest provider of generic drugs, accounting for about 20% of the global supply by volume. The Indian pharmaceutical sector is a behemoth, valued at over USD 50 billion and exporting to more than 200 countries, including highly regulated markets in North America and Europe.

The Existing Regulatory Framework: A Fragmented and Archaic Structure

The legal backbone for drug regulation in India is The Drugs and Cosmetics Act, 1940, and its corresponding Rules of 1945. This legislation, enacted during the British colonial era, was designed for a far simpler pharmaceutical landscape. Today, it struggles to effectively govern a complex industry characterized by advanced biologics, sophisticated medical devices, and global supply chains.

The most significant challenge embedded in this framework is its dual regulatory structure. Power is divided between the central government and the state governments, creating a system fraught with inconsistencies and enforcement gaps.

1. Central Drugs Standard Control Organisation (CDSCO): Operating under the Ministry of Health and Family Welfare, the CDSCO is the national regulatory body. Its primary responsibilities include:

   • Approval of new drugs for marketing.
   • Conducting clinical trials.
   • Setting standards for drugs.
   • Controlling the quality of imported drugs.
   • Coordinating the activities of State Drug Regulatory Authorities (SDRAs).
   • Granting licenses for specialized and critical categories of drugs, such as vaccines, blood products, and intravenous fluids.

2. State Drug Regulatory Authorities (SDRAs): Each state has its own SDRA, which is responsible for the day-to-day regulation of drug manufacturing, sales, and distribution within its jurisdiction. Their key functions include:

   • Issuing licenses for the manufacture of most drugs and cosmetics.
   • Approving drug formulations for sale within the state.
   • Carrying out inspections of manufacturing facilities and distribution channels.
   • Enforcing drug quality standards through sampling and testing.

This division of power, while intended to reflect India’s federal structure, has created a regulatory labyrinth. The CDSCO sets the standards, but the SDRAs are largely responsible for enforcing them at the ground level. This leads to a significant “enforcement deficit,” where the quality of regulation can vary dramatically from one state to another, depending on the resources, expertise, and political will of the local authority. Companies have been known to engage in regulatory arbitrage, choosing to set up manufacturing plants in states with weaker regulatory oversight. This fragmentation is widely seen as the root cause of the quality control failures that have recently tarnished the industry’s reputation.

Core Challenges and Systemic Flaws Exposed

The recent cough syrup tragedies were not isolated incidents but rather symptoms of deeper, systemic problems plaguing India’s pharmaceutical regulatory environment.

1. Inadequate and Inconsistent Quality Enforcement: The primary flaw is the inconsistent enforcement of Good Manufacturing Practices (GMP). While GMP guidelines are laid out in Schedule M of the Drugs and Cosmetics Rules, compliance has been patchy. Many of the 10,500 drug manufacturing units in the country, especially the Micro, Small, and Medium Enterprises (MSMEs) that form the industry’s backbone, have failed to upgrade their facilities to meet modern standards. Inspections are often infrequent, and the inspectors themselves may lack the specialized training required to audit complex manufacturing processes. The contamination with DEG and EG, cheap industrial solvents sometimes unscrupulously used as substitutes for more expensive but non-toxic solvents like propylene glycol, is a direct result of this breakdown in quality control and supply chain integrity.

2. Outdated Legislative Framework: The Drugs and Cosmetics Act of 1940 is fundamentally ill-equipped for the 21st century.

• It lacks specific provisions for modern therapeutic products like stem cells, gene therapies, and other biologics.
• It does not adequately regulate medical devices, which are currently treated as a subset of ‘drugs’, failing to address their unique engineering and safety aspects.
• The rise of e-pharmacies and online drug sales has created a regulatory grey area that the old law cannot effectively manage.
• The penalties prescribed for non-compliance, particularly for manufacturing substandard drugs, are often not stringent enough to act as a credible deterrent.

3. Severe Resource and Capacity Constraints: Both the CDSCO and the SDRAs are chronically understaffed and under-resourced. A 2022 parliamentary report highlighted that many states have a severe shortage of drug inspectors, with some having less than 50% of the sanctioned posts filled. The existing inspectors are often overburdened, responsible for overseeing hundreds of manufacturing units and thousands of pharmacies. Furthermore, the network of government drug testing laboratories is inadequate. Many labs lack sophisticated testing equipment, such as mass spectrometers, which are necessary to detect contaminants like DEG and EG at trace levels. This capacity gap means that only a tiny fraction of the drugs circulating in the market are ever tested for quality.

Analogy: Imagine a national highway system where the rules of the road (speed limits, traffic signals) are set by the central government, but the policing of these rules is left to small, underfunded local police forces in each town. The result would be chaotic and dangerous, with safe driving in one town and lawlessness in the next. This is analogous to India’s dual drug regulatory system.

Sweeping Reforms on the Anvil: A New Era of Regulation?

In response to the intense domestic and international pressure, the Indian government has initiated a series of sweeping reforms aimed at overhauling the entire regulatory architecture. These initiatives represent the most significant push for change in the sector’s history.

1. Mandatory Implementation of the Revised Schedule M: The most immediate and impactful reform has been the decision to make compliance with the revised Schedule M of the Drugs and Cosmetics Rules mandatory for all pharmaceutical manufacturers. This move, announced in late 2023, aims to elevate Indian GMP standards to be on par with global benchmarks, particularly those set by the WHO (WHO-GMP).

The revised Schedule M introduces several critical requirements:

• Comprehensive Quality Management System: Mandates a pharmaceutical quality system (PQS), quality risk management (QRM), and regular product quality reviews.
• Modern Infrastructure: Requires advanced heating, ventilation, and air-conditioning (HVAC) systems, cleanroom classifications, and controlled environmental conditions to prevent cross-contamination.
• Advanced Process Controls: Introduces computerized systems for process control and data management to ensure integrity and traceability.
• Supply Chain Validation: Requires robust qualification and validation of all suppliers of raw materials and packaging materials.

The government has set a phased timeline for implementation: larger companies with a turnover of over ₹250 crore were given six months to comply, while MSMEs with a turnover below ₹250 crore were given a 12-month period. This is a monumental shift, as it forces thousands of smaller firms to either invest heavily in upgrading their facilities or risk having their licenses revoked.

2. The Drugs, Medical Devices, and Cosmetics Bill, 2023: This proposed legislation is the cornerstone of the long-term reform strategy. It aims to replace the 1940 Act with a modern, unified, and robust legal framework. While the bill is still under review and has been examined by a Parliamentary Standing Committee, its key proposals signal the government’s direction:

Mnemonic for Key Pillars of the Proposed 2023 Bill: To remember the core changes, use the mnemonic “DEVICES”:

• D - Definitions expanded for new-age therapeutics.
• E - E-pharmacies brought under a clear regulatory net.
• V - Vigilance and post-market surveillance strengthened.
• I - Independent authority for medical devices (MDTAB).
• C - Centralization of licensing to ensure uniformity.
• E - Enhanced penalties to deter malpractices.
• S - Statutory provisions for clinical trial compensation.

3. Risk-Based Inspection and Unified IT Platform: The government is moving away from a one-size-fits-all inspection model towards a risk-based approach. This involves identifying high-risk manufacturing units based on their product category, compliance history, and other intelligence, and subjecting them to more frequent and rigorous audits. To support this, a unified, nationwide IT platform is being developed. This digital portal will connect the CDSCO and all SDRAs, creating a single window for licensing, inspection reports, test results, and recall information. This is expected to enhance transparency, improve data sharing, and prevent manufacturers from exploiting the gaps between different state regulators.

Statistic: According to government data released in 2023, nationwide risk-based inspections of 162 pharmaceutical firms resulted in the issuance of show-cause notices to 147 of them, and production was stopped in 31 firms, highlighting the widespread nature of compliance issues.

Critical Policy Appraisal

The path to reform is complex and faces significant hurdles. A balanced view reveals both the opportunities and the challenges ahead.

Analytical Lens: UPSC Focus (Mains & Prelims)

1. Conceptual Basis: The legal framework for this topic rests on The Drugs and Cosmetics Act, 1940, and its associated Rules. The future of regulation is shaped by the proposed Drugs, Medical Devices, and Cosmetics Bill, 2023, and the executive enforcement of the revised Schedule M (WHO-GMP).

2. UPSC Integration: Connecting the Dots:

• GS Paper 2 (Polity & Governance): This topic is a classic case study in Indian federalism, highlighting the tensions between Centre and State powers in a Concurrent List subject (Adulteration of foodstuffs and other goods). It also relates to the functioning of regulatory bodies, issues of public health, and the formulation of government policies.
• GS Paper 3 (Economy): The pharmaceutical industry is a vital component of the Indian economy and the ‘Make in India’ initiative. The regulatory crisis directly impacts manufacturing, exports, and industrial policy. The challenges faced by MSMEs are also a key theme.
• GS Paper 2 (International Relations): India’s reputation as the ‘Pharmacy of the World’ is a significant element of its soft power. This crisis affects India’s global standing, its relationship with international bodies like the WHO, and its role in global health security.

3. Long-Term Impact and Policy Relevance: The successful implementation of these reforms is existentially important for India. Failure to act decisively could lead to ‘de-risking’ by global buyers, who may shift their supply chains to other countries, eroding India’s hard-won market share. Conversely, if India successfully transforms its regulatory system into a world-class, transparent, and efficient model, it could solidify its position as a global pharmaceutical leader for decades to come. This would not only be an economic victory but also a major boost to its geopolitical standing. The policy focus must be on hand-holding MSMEs through the transition, investing massively in regulatory capacity, and achieving a political consensus on a unified legal framework.

4. Prelims Practice Question (MCQ):

Question: With reference to drug regulation in India, what is the primary objective of the ‘revised Schedule M’ that was recently made mandatory? a) To regulate the pricing of essential medicines. b) To lay down rules for the online sale of pharmaceuticals. c) To align Indian Good Manufacturing Practices (GMP) with global WHO-GMP standards. d) To create a separate regulatory body for medical devices.

Answer: (c) To align Indian Good Manufacturing Practices (GMP) with global WHO-GMP standards. Explanation: Schedule M of the Drugs and Cosmetics Rules, 1945, specifically deals with Good Manufacturing Practices. The recent revision and its mandatory implementation are aimed at upgrading the quality assurance systems, infrastructure, and process controls in Indian manufacturing units to meet the more stringent standards set by the World Health Organization (WHO-GMP), thereby enhancing the quality and safety of drugs.

5. Mains Sample Question (15 Marks):

Question: “The recent crisis in India’s pharmaceutical sector is not merely a case of isolated quality failures but a symptom of a deeply fragmented and archaic regulatory structure.” Critically analyze this statement. Discuss the key reforms initiated by the government and evaluate their potential to restore India’s credibility as the ‘Pharmacy of the World’.

Mind Map Outline (Revision Structure)

• India’s Pharmaceutical Regulatory Crisis
  • Core Issue: Contaminated cough syrups leading to child deaths (Gambia, Uzbekistan).
    • Contaminants: Diethylene Glycol (DEG), Ethylene Glycol (EG).
    • Immediate Impact: WHO alerts, loss of global trust.
  • Existing Regulatory Framework (The Drugs and Cosmetics Act, 1940)
    • Dual Control Structure (The Core Problem)
      • CDSCO (Central Body):
        • Roles: New drug approval, import control, setting standards.
      • SDRAs (State Bodies):
        • Roles: Licensing, inspection, ground-level enforcement.
    • Consequences of Fragmentation:
      • Inconsistent enforcement.
      • Regulatory arbitrage by companies.
      • Enforcement deficit.
  • Systemic Flaws and Challenges
    • Quality Control Failures: Patchy compliance with Schedule M (GMP).
    • Outdated Legislation (1940 Act):
      • Fails to address medical devices, e-pharmacies, modern biologics.
      • Weak penalties.
    • Resource & Capacity Deficits:
      • Shortage of drug inspectors.
      • Inadequate testing laboratories.
  • Major Government Reforms (Post-Crisis)
    • Mandatory Revised Schedule M:
      • Goal: Align with WHO-GMP standards.
      • Key Features: Quality management systems, modern infrastructure, process controls.
      • Implementation: Phased timeline for large firms and MSMEs.
    • The Drugs, Medical Devices, and Cosmetics Bill, 2023:
      • Objective: Replace the 1940 Act.
      • Key Provisions (Mnemonic: DEVICES):
        • Separate regulation for medical devices (MDTAB).
        • Regulation of E-pharmacies.
        • Centralized licensing authority (proposed).
        • Enhanced penalties.
    • Risk-Based Inspections & Unified IT Platform:
      • Targeting high-risk units.
      • Creating a transparent, unified digital portal.
  • Analysis and Way Forward
    • Critical Policy Appraisal (Table):
      • Challenges: MSME resistance, federalism issues, capacity building.
      • Opportunities: Global competitiveness, uniform quality, restoring trust.
    • UPSC Focus ( Lens):
      • Conceptual Basis: Act of 1940, Bill of 2023, Schedule M.
      • Inter-Topic Linkages:
        • Polity (Federalism, Regulatory Bodies).
        • Economy (Make in India, Exports, MSMEs).
        • IR (Soft Power, WHO).
      • Practice Questions: Prelims MCQ and Mains Question.